| Not Yet Recruiting | RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) NCT07492316 | University of Florida | Phase 1 |
| Recruiting | GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults NCT07087002 | Stanford University | Phase 1 |
| Recruiting | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medullobla NCT05096481 | Nationwide Children's Hospital | Phase 2 |
| Withdrawn | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine NCT06466798 | Jeffrey Treiber | Phase 1 |
| Recruiting | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors NCT05278208 | Nationwide Children's Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma NCT04743661 | Pediatric Brain Tumor Consortium | Phase 2 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer NCT04521946 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Ch NCT04501718 | Beijing Sanbo Brain Hospital | Phase 2 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Fimepinostat in Treating Brain Tumors in Children and Young Adults NCT03893487 | Sabine Mueller, MD, PhD | EARLY_Phase 1 |
| Active Not Recruiting | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors NCT03598244 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma NCT03299309 | Daniel Landi | Phase 1 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Completed | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies fo NCT03434262 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors NCT03387020 | Pediatric Brain Tumor Consortium | Phase 1 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diff NCT02359565 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors NCT02271711 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurren NCT01217437 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CN NCT00983398 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |